Ph 2 Elacestrant in ER Positive Uterine Sarcomas
NCT07467772
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Uterine Sarcoma
- Uterine Leiomyosarcoma
- Endometrial Stromal Sarcoma
- ESS
- Perivascular Epithelioid Cell Tumors
- Uterine Adenosarcoma
- Uterine PEComa
- Estrogen Receptor Positive Tumor
- uLMS
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- May 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.